Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine tartrate
Drug ID BADD_D01956
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D02558
MeSH ID D000068836
PubChem ID 6918078
TTD Drug ID D0WY5Q
NDC Product Code 60687-574; 55111-355; 62756-146; 62756-148; 62756-145; 75834-135; 51991-794; 33342-090; 49706-1826; 65862-650; 51991-795; 71209-012; 71209-015; 0904-6587; 62704-0122; 33342-092; 65862-651; 46708-066; 75834-134; 55111-354; 50379-0012; 33342-089; 46708-873; 71209-014; 65862-649; 65862-648; 62756-147; 0904-7107; 62756-136; 65372-1152; 55111-352; 55111-066; 71209-013; 55111-353; 65862-612; 75834-136; 72241-011; 33342-091; 53104-7571; 46708-064; 72241-013; 51991-796; 72241-012; 75834-133; 51991-793; 72241-014; 46708-065; 70518-3012; 46708-063
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C18H28N2O8
CAS Registry Number 129101-54-8
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T99799Not Available
DiarrhoeaCholinesteraseP06276T99799Not Available
DizzinessCholinesteraseP06276T99799Not Available
VomitingCholinesteraseP06276T99799Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Abscess11.01.08.001--Not Available
Adams-Stokes syndrome02.03.01.001; 17.02.04.010--Not Available
Adenocarcinoma16.16.01.004--Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Amnesia19.20.01.001; 17.03.02.001--
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Anaemia vitamin B12 deficiency14.12.02.001; 01.03.01.001--Not Available
Aneurysm24.02.01.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Anorectal disorder07.03.01.001--Not Available
Anxiety19.06.02.002--
Apathy19.04.04.002--Not Available
Aphasia19.21.01.001; 17.02.03.001--
Apnoea22.02.01.001--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site irritation12.07.01.003; 08.02.01.003--Not Available
Application site oedema08.02.01.020; 12.07.01.020--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Application site rash12.07.01.016; 08.02.01.016; 23.03.13.008--Not Available
Apraxia19.21.01.002; 17.02.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 15 Pages